When Pediatric MATCH launched in 2017, it was estimated that there would be a match rate of about 10 percent, meaning one-in-ten participants were expected to be eligible to receive treatment with at least one drug. Early results, however, are much more promising: An analysis of 400 patients screened reveals a match rate of 24 percent.Read More
Childhood cancer advocates, including our own founder Susan L. Weiner, were among the thousands of oncology experts in attendance at this week’s American Association for Cancer Research (AACR) Annual Meeting in Atlanta.
We’re particularly proud that Susan was part of a major symposium panel on pediatric oncology with a dual prong focus on implementation of the RACE for Children Act and on the global potential of the ACCELERATE multi-stakeholder platform.Read More
In both 2017 and 2018, we conducted an online survey in partnership with the Patient Advocate Foundation. We heard from nearly 450 caregivers and survivors , and below we share a few key findings related to survivorship, financial hardship, and coverage challenges.
At the Children’s Cause, we’re using this data to support a variety of policy proposals and projects in the works. We thank all the families and survivors who are helping to inform our advocacy work by sharing their experiences and challenges. Your input makes us a stronger voice for our children in Washington and around the country.Read More
Cancer is the leading cause of death from disease among children and adolescents in the United States. Although substantial progress has been made in the treatment of several types of childhood cancer over the past five decades, progress against other types has been limited.
With your help, we can continue to make our children with cancer a priority for research funding during Cancer Research Month and all year long.Read More
Our president and founder Susan L. Weiner, PhD, presented at last week's ACCELERATE pediatric oncology conference in Brussels. Dr. Weiner discussed the critical need for a public private partnership (PPP) to develop drugs for children when there is no associated adult development program.
Dr. Weiner’s presentation continues a Children’s Cause effort to identify novel business and collaborative arrangements to address this development gap...Read More